Jump to content

LSR-3000

Add links
From Wikipedia, the free encyclopedia

LSR-3000
Clinical data
Other namesLSR3000
Routes of
administration		Oral[1]
Drug classSerotonin receptor agonist; Psychoplastogen

LSR-3000 is a non-selective serotonin receptor agonist and psychoplastogen of the tryptamine family which is under development for the treatment of neurological disorders.[1][2][3] The drug is taken by mouth.[1] It is under development by Lusaris Therapeutics.[1][2][3] As of November 2022, LSR-3000 is in the research or discovery stage of development.[1][2][3] Its chemical structure does not yet appear to have been disclosed.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "LSR 3000". AdisInsight. 16 November 2022. Retrieved 16 February 2025. LSR 3000 is a small molecule, serotonergic neuroplasogen therapeutic being developed by Lusaris Therapeutics, for the treatment of neuropsychiatric and [...]
  2. ^ a b c "Delving into the Latest Updates on LSR-3000 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ^ a b c Hargreaves B (14 November 2022). "Psychedelic startup launches with $60m and Catalent tech". outsourcing-pharma.com. OutsourcingPharma. Alongside LSR-1019, the biotech also has LSR-2000 in a late-stage discovery program evaluating serotonergic neuroplastogens for the prevention of migraines and cluster headaches. In addition, LSR-3000 is at the discovery phase for developing therapies suitable for chronic dosing by maintaining broad serotonergic receptor activation.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=LSR-3000&oldid=1275993111"